PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?

Zijun Y. Xu‐Monette(Duke University), Ken H. Young(Duke Medical Center), Mingzhi Zhang(Chinese Academy of Sciences), Jianyong Li(Jiangsu Province Hospital)

Frontiers in Immunology

December 4, 2017

10.3389/fimmu.2017.01597

Cited by 296

Related Papers

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

|New England Journal of Medicine|2015|1.6k

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

|Blood|2013|683

Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

|Journal of Clinical Oncology|2012|682

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas

|Blood|2017|429

Complete Surgical Excision Is Essential for the Management of Patients With Breast Implant–Associated Anaplastic Large-Cell Lymphoma

|Journal of Clinical Oncology|2015|418